We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A picture of Michele Trott, PhD

Michele Trott, PhD profile page


Michele Trott (nee Wilson) is a New Zealand-based science writer who pursues freelance writing projects alongside her in-house role as a scientific content writer at Izon Science. After completing her PhD (Endocrinology) at Lincoln University (NZ), Michele began pursuing her science writing career with Technology Networks in the UK. There, she spent 12 months covering a maternity leave role as a science editor, and managed the cell science, biopharma and diagnostics communities. Upon her arrival back in NZ, Michele established “Choice Science Writing” and became a full-time freelance science writer, working with life science marketing agencies, biotech companies – and of course, Technology Networks – to produce engaging articles and blog posts. In April 2021, she took up the opportunity to join the team at Izon Science, a company that enables the precise separation and analysis of extracellular vesicles and other nanoparticles.


Got a Question for Michele Trott, PhD?


Get in touch using the contact form linked here and we’ll get back to you shortly.



Published Content
Total: 111
Top 10 Biopharma News Stories of 2018 content piece image
Listicle

Top 10 Biopharma News Stories of 2018

It has been a big year for the biopharma world. In case you missed them, here is a list of the top 10 most-read biopharma news stories we have published in 2018.
8 Characters You’ll Find in Every Lab content piece image
Infographic

8 Characters You’ll Find in Every Lab

In this poster we highlight eight characters you will find in every lab. Which character are you most like?
Diagnostic Tests for Influenza content piece image
Infographic

Diagnostic Tests for Influenza

Doctors are not required to confirm the presence of the
influenza virus before they prescribe antiviral medication. So, why test for influenza? Download this infographic to find out why, and how.
Challenges for Biopharma content piece image
Infographic

Challenges for Biopharma

The pursuit for innovative therapies in the biopharma industry is not without its challenges. Anticipating and addressing these hurdles can make or break the success of your biopharmaceutical product, regardless of the therapy type. Download this infographic for a snapshot of 30 insights on key challenges in the drug development pipeline.
News

The First Organ to be Bioprinted in Space

Russian astronauts onboard a spacecraft have reportedly bioprinted a mouse thyroid. This is definitely a world-first in outer space bioprinting.
News

The First Organ to be Bioprinted in Space

Russian astronauts onboard a spacecraft have reportedly bioprinted a mouse thyroid. This is definitely a world-first in outer space bioprinting.
Influenza: Pathology, Diagnosis and Prevention  content piece image
Infographic

Influenza: Pathology, Diagnosis and Prevention

A century has passed since the 1918 global flu pandemic, aka the ‘Spanish flu’. Back in the early 1900s, the virus was a relatively novel concept. Since then, our understanding of viruses has come a long way, as have our diagnostics tools, and control and preventative strategies.
Newborn Screening content piece image
Infographic

Newborn Screening

Neonatal screening is designed to identify newborn babies with conditions that are treatable, but not clinically evident in the newborn period. Download this infographic to learn about one of the most successful public health screening programs to date.
Industry Insight

Immunotherapy Response Prediction in Urothelial Cancer

While immunotherapy holds great promise for cancer treatment, challenges persist around limited response rate and severe immune-related adverse events. We caught up with Dr. Georg Lautscham, CEO of Protagen, to find out how the prediction of immunotherapy response can be improved for people with urothelial cancer.
Industry Insight

Immunotherapy Response Prediction in Urothelial Cancer

While immunotherapy holds great promise for cancer treatment, challenges persist around limited response rate and severe immune-related adverse events. We caught up with Dr. Georg Lautscham, CEO of Protagen, to find out how the prediction of immunotherapy response can be improved for people with urothelial cancer.
Advertisement